Pfizer Inc (PFE)

Pfizer is one of the world’s oldest and largest pharmaceutical companies, a descendant of a chemical dye manufacturer founded in Brooklyn in 1849. The company is known broadly for Viagra, for its portfolio of vaccines including the COVID-19 vaccine developed with BioNTech, for cancer drugs, and for primary-care medicines that treat hypertension and cholesterol. But this array of famous names barely hints at the scale and complexity of what Pfizer actually does. The company operates more like a holding company for thousands of small pharmaceutical businesses, each selling a different drug or class of drugs. Some of those drugs are blockbusters taken by millions of people daily. Others are niche therapies for rare diseases. Some are decades old and sell steadily at low margin. Others are new, protected by patents, and highly profitable. The entire portfolio is held together by the obligation to keep earning profits to fund the massive research and development effort required to discover and develop new drugs. This fundamental asymmetry — between the need to fund future innovation and the pressure to maximise current earnings — defines pharmaceutical company strategy.

Pfizer is a research-driven business with a 170-year history. The company built its initial fortune in antibiotics, particularly penicillin, which it mass-produced during and after World War II. It later became known for blockbuster drugs like Lipitor (for cholesterol), Celebrex (for arthritis), and Viagra (for erectile dysfunction). In recent decades, Pfizer has invested heavily in vaccines and cancer medicines, two of the fastest-growing and most profitable categories in pharma. The company manufactures in dozens of countries, sells globally through a network of distributors and direct relationships with healthcare systems, and operates within a complex web of patent protections, price regulations, and reimbursement systems that vary dramatically from country to country.

Patent cliffs and the treadmill of innovation

The economics of pharmaceutical companies rest entirely on patents. When Pfizer develops a new drug, it receives a patent that typically lasts twenty years from filing. During that patent period, the company has a monopoly on selling that drug — competitors cannot make a generic version — so Pfizer can charge premium prices. The drug reaches the market, spends several years gaining adoption, and eventually reaches peak sales in year five to ten after approval. If the drug is successful and widely prescribed, revenues can be enormous.

But patents expire. Once the patent lapses, generic manufacturers can produce and sell chemically identical versions at a fraction of the branded price. This loss of patent protection is called a patent cliff, and it is one of the defining features of pharmaceutical company financial statements. A drug generating a billion dollars in annual revenue can see revenue collapse to tens of millions once generics arrive, because healthcare systems and individual patients naturally switch to cheaper alternatives. Pfizer’s financial reports show multiple drugs each year moving from branded to generic, creating revenue headwinds that the company must replace with new drugs that are still on patent.

This creates a treadmill. Pfizer must spend billions annually on research and development — typically 15 to 20 percent of revenue — to discover and develop new drugs to replace those losing patent protection. If Pfizer fails to generate enough new drugs, revenue and profit decline. If Pfizer succeeds, it can maintain and grow the business. But success is far from guaranteed. Drug discovery is a hit-driven business: most drugs that enter development fail before approval. Out of a thousand potential compounds screened, perhaps only one becomes a marketable drug. The company cannot know in advance which ones will work, so it must place many bets.

The company has accelerated its transition toward oncology (cancer) and immunology (vaccines and immune-system drugs) because these categories are less subject to generic competition — they are more complex, patented therapies that command high prices even after other generics have eroded a company’s traditional portfolio. This shift has required years of investment in research capabilities and acquisition of smaller biotech companies with specialized expertise.

How Pfizer makes and sells drugs

Pfizer operates as multiple businesses stitched together into one financial entity. The company develops, manufactures, and sells medicines across distinct therapeutic categories: primary care (general medical conditions like high blood pressure and high cholesterol), specialty care (complex conditions requiring careful dosing and monitoring), oncology (cancer), vaccines, and consumer health (over-the-counter medicines).

Each therapeutic area has its own research teams, manufacturing facilities, and sales forces. A cardiologist treating a patient with heart disease might prescribe a Pfizer drug without knowing or caring that Pfizer also makes cancer drugs or vaccines. The company functions partly as an integrated whole and partly as a portfolio of separate businesses, and this dual nature shapes how it allocates resources and makes strategic decisions.

Manufacturing is complex and heavily regulated. A pharmaceutical plant must meet strict standards for cleanliness, quality control, and documentation. Creating a new manufacturing facility can take years and cost hundreds of millions of dollars. Once built, the facility is dedicated to a specific drug or set of drugs, and changes to the process require approval from regulators. This makes manufacturing somewhat inflexible — if demand for a drug surges, Pfizer cannot quickly ramped up production, and if demand falls, the company has expensive facilities that are underutilised.

Sales happen through multiple channels. In the United States, Pfizer employs salespeople who visit doctors’ offices to educate physicians about drugs and encourage prescribing. In other countries with government-run healthcare systems, Pfizer negotiates directly with government bodies or insurance companies over pricing and formulary placement (whether a drug is covered). The company also sells through wholesale and retail pharmacies, hospital buying groups, and global distributors. This multi-channel approach gives Pfizer reach but also complexity — different customer types have different incentives and negotiating power.

Pricing, patents, and the regulatory landscape

Pharmaceutical pricing is one of the most contentious and complex aspects of the industry. In the United States, drug manufacturers can largely set their own prices, and prices for some drugs have risen steeply — a phenomenon that has attracted political attention. In Europe and many other developed countries, governments regulate drug prices through various mechanisms: some countries negotiate prices directly with manufacturers, others use reference pricing where they set a maximum price based on what similar drugs cost. In developing countries, prices are typically much lower because of lower ability to pay.

This fragmented pricing landscape means Pfizer cannot simply set one global price. It must navigate different regulatory frameworks in each jurisdiction, balancing the desire to charge high prices in wealthy markets against the desire to reach patients in poorer countries and avoid regulatory backlash. The company has historically tried to maintain high prices in developed markets while offering large discounts and donations in developing markets.

Patent strategy is central to Pfizer’s financial planning. The company extends patent life where possible through “evergreening” — making small improvements to a drug and filing a new patent application, extending the period before generics can enter. Regulatory approval for new indications (new uses for an existing drug) can also extend marketability. But patent extensions have limits, and eventually all patents expire. Pfizer’s research engine must continually produce new blockbusters to offset the revenue lost to generics.

Acquisitions and the hunt for scale

Pfizer has grown partly through acquisition. The company acquired Warner-Lambert in 2000 (for Lipitor, a blockbuster cholesterol drug), Pharmacia in 2003, and Medivation in 2016 (for Xtandi, a cancer drug). Each acquisition brought new drugs and research capabilities but also integration challenges and questions about whether the price paid was justified by the value created. The largest and most significant was the planned but ultimately abandoned merger with AstraZeneca in 2014, which would have created a still-larger pharmaceutical company but which UK regulators ultimately blocked.

In 2021 and 2022, Pfizer made significant acquisitions in oncology and specialty care, spending tens of billions to buy companies like Arena Pharmaceuticals and Biohaven. The logic was to accelerate the portfolio’s shift away from aging, lower-margin drugs toward higher-growth, higher-margin oncology and specialty therapies. Whether these acquisitions prove successful will depend on how well the acquired companies’ drugs perform clinically and commercially in Pfizer’s hands.

Acquisition strategy is risky in pharma because the value of a drug depends on whether it succeeds clinically (does it actually help patients better than alternatives) and commercially (do doctors prescribe it and do patients use it). Paying billions for a company whose most important drug is still in late-stage trials carries enormous risk that the drug will fail or underperform.

The pandemic windfall and return to normal

Pfizer gained enormous visibility during the COVID-19 pandemic as the developer of one of the earliest and most widely used COVID-19 vaccines. The vaccine was a genuine scientific achievement, developed rapidly using new mRNA technology, and was approved and widely distributed, saving millions of lives. It was also enormously profitable: the vaccine generated tens of billions in revenue for Pfizer and BioNTech combined at the peak.

But pandemic-driven demand is not sustainable. As the crisis abated and vaccination rates stabilised, demand for COVID-19 vaccines fell to much lower levels. Pfizer’s financial performance in 2022 and 2023 faced major headwinds from the collapse in vaccine revenues. This created a harsh reminder that pharmaceutical companies cannot rely on extraordinary events to drive profits — they must have a sustainable underlying business. In Pfizer’s case, this means the company’s base portfolio, minus pandemic revenues, is growing modestly or slowly. Rebuilding growth requires successful new drug launches from the pipeline, which will take years.

Development risk and pipeline

Pfizer’s future depends on its clinical pipeline — the collection of drugs in development at various stages. A typical timeline for drug development is ten to fifteen years from initial discovery to FDA approval. Drugs start with basic research and screening, move into laboratory and animal testing, and then enter clinical trials (Phase I, II, and III, each building evidence of safety and efficacy). After approval, post-market surveillance (Phase IV) monitors for long-term side effects. At each stage, most drugs fail — they do not work, have unacceptable side effects, or cannot be manufactured at scale.

Pfizer discloses its development pipeline publicly, listing drugs in each stage of development and their therapeutic area. Investors scrutinise this pipeline to assess whether Pfizer has enough promising drugs to replace the revenue lost to patent expirations and generic competition. A strong pipeline with multiple potentially blockbuster drugs in late-stage trials signals healthy future revenues. A thin pipeline with few late-stage drugs suggests future revenue pressure.

The company has been shifting resources toward oncology and specialty care, which makes sense commercially — these categories command premium prices and have less generic pressure — but it requires confidence that Pfizer’s research teams can win in competitive spaces where many companies are racing to discover the next blockbuster cancer drug.

How to research Pfizer as an investment

Pfizer’s annual 10-K (SEC CIK 0000078003) provides detailed revenue breakdown by therapeutic area and geography, showing which parts of the business are growing and which are shrinking. The company discloses its clinical pipeline with detail on the stage of development and therapeutic area of each drug in development. The research and development section explains the company’s strategic focus and allocation of R&D spending.

Key metrics to track: revenue trends by business segment, particularly monitoring how much revenue is coming from mature, lower-margin drugs versus newer, higher-margin therapies. Free cash flow generation shows whether profits translate into actual cash. The composition of revenue (how much is blockbuster drugs, how much is specialty or oncology) indicates strategic progress. Patent expiration schedules show upcoming revenue headwinds from generic competition. Pipeline progress — drugs advancing to later-stage trials or receiving approvals — signals future revenue potential. And gross margins and operating margins by segment reveal pricing power and cost management.

The most important question for Pfizer’s future is whether the company can successfully transition from a company whose profits are driven by aging drugs toward one whose growth comes from newer, specialty, and oncology therapies. If that transition succeeds, Pfizer could stabilise or grow earnings. If it fails, the company faces years of declining revenue and contracting margins as blockbusters lose patent protection and no successful replacements emerge.